A recombined fusion protein PTD-Grb2-SH2 inhibits the proliferation of breast cancer cells in vitro

International Journal of Oncology

Volumn 42, Issue 3, 2013, Pages 1061-1069

  Yin, Jikai ^a   Cai, Zhongliang ^b   Zhang, Li ^a   Zhang, Jian ^c   He, Xianli ^a   Du, Xilin ^a   Wang, Qing ^a   Lu, Jianguo ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Growth factor receptor bound protein 2; Protein transduction domain; Src homology 2 domain

Indexed keywords

ANTINEOPLASTIC AGENT; HYBRID PROTEIN; PTD GRB2 SH2 FUSION PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL MEMBRANE; CELL NUCLEUS MEMBRANE; CELL PROLIFERATION; CELLS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PURIFICATION; EXPRESSION VECTOR; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MOLECULAR WEIGHT; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; WESTERN BLOTTING;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION; GRB2 ADAPTOR PROTEIN; HUMANS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SRC HOMOLOGY DOMAINS; TRANSDUCTION, GENETIC;

EID: 84873682711     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1768     Document Type: Article

References (38)

1. DeSantis C, Siegel R, Bandi P and Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin 61: 409-418, 2011.
2. Harris AL, Nicholson S, Sainsbury JR, Farndon J and Wright C: Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 34: 123-131, 1989. (Pubitemid 20061773)
3. Sainsbury JR, Malcolm AJ, Appleton DR, Farndon JR and Harris AL: Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 38: 1225-1228, 1985. (Pubitemid 16215034)
4. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004. (Pubitemid 39100473)
5. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989. (Pubitemid 19147683)
6. Foster CS, Gosden CM and Ke Y: HER2/neu expression in cancer: the pathologist as diagnostician or prophet? Hum Pathol 34: 635-638, 2003. (Pubitemid 36875507)
7. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P and Norton L: Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis. Cancer 75: 1320-1326, 1995.
8. Carlomagno C, Perrone F, Gallo C, et al: c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14: 2702-2708, 1996. (Pubitemid 26329655)
9. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10: 1049-1056, 1992.
10. Bianco R, Melisi D, Ciardiello F and Tortora G: Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 42: 290-294, 2006. (Pubitemid 43132883)
11. Chardin P, Cussac D, Maignan S and Ducruix A: The Grb2 adaptor. FEBS Lett 369: 47-51, 1995.
12. Seger R and Krebs EG: The MAPK signaling cascade. FASEB J 9: 726-735, 1995.
13. Di Fulvio M, Henkels KM and Gomez-Cambronero J: Short hairpin RNA-mediated stable silencing of Grb2 impairs cell growth and DNA synthesis. Biochem Biophys Res Commun 357: 737-742, 2007. (Pubitemid 46653842)
14. Machida K and Mayer BJ: The SH2 domain: versatile signaling module and pharmaceutical target. Biochim Biophys Acta 1747: 1-25, 2005. (Pubitemid 40170450)
15. Pawson T: Protein modules and signalling networks. Nature 373: 573-580, 1995.
16. Mayer BJ, Jackson PK and Baltimore D: The noncatalytic src homology region 2 segment of abl tyrosine kinase binds to tyrosine-phosphorylated cellular proteins with high affinity. Proc Natl Acad Sci USA 88: 627-631, 1991. (Pubitemid 21915519)
17. Mayer BJ, Jackson PK, Van Etten RA and Baltimore D: Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Mol Cell Biol 12: 609-618, 1992.
18. Schwarze SR, Hruska KA and Dowdy SF: Protein transduction: unrestricted delivery into all cells? Trends Cell Biol 10: 290-295, 2000. (Pubitemid 30387038)
19. Lindgren M, Hallbrink M, Prochiantz A and Langel U: Cell penetrating peptides. Trends Pharmacol Sci 21: 99-103, 2000.
20. Liang Y, Sun Q, Jiang S, et al: Construction and expression of a vector containing protein transduction domain and bcr/abl fusion gene. Zhonghua Xue Ye Xue Za Zhi 23: 5-8, 2002 (In Chinese).
21. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
22. Sangadala S, Okada M, Liu Y, Viggeswarapu M, Titus L and Boden SD: Engineering, cloning, and functional characterization of recombinant LIM mineralization protein-1 containing an N-terminal HIV-derived membrane transduction domain. Protein Expr Purif 65: 165-173, 2009.
23. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001. (Pubitemid 33674041)
24. Lung FD and Tsai JY: Grb2 SH2 domain-binding peptide analogs as potential anticancer agents. Biopolymers 71: 132-140, 2003.
25. Kim D, Jeon C, Kim JH, et al: Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo. Exp Cell Res 312: 1277-1288, 2006.
26. Schwarze SR, Ho A, Vocero-Akbani A and Dowdy SF: In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572, 1999. (Pubitemid 29420581)
27. Tan M, Lan KH, Yao J, et al: Selective inhibition of ErbB2 overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res 66: 3764-3772, 2006.
28. Harada H, Kizaka-Kondoh S and Hiraoka M: Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer 13: 16-26, 2006.
29. Sorriento D, Campanile A, Santulli G, et al: A new synthetic protein, TAT-RH, inhibits tumor growth through the regulation of NFkappaB activity. Mol Cancer 8: 97, 2009.
30. Liang YJS, Han H, Liu L, Sun Q, Chen R, Wu R, Du J and Li Q: TAT PTD-BCR/ABL SH3 fusion protein induces the apoptosis of K562 leukemic cell line. J Fourth Mil Med Univ 23: 4, 2002.
31. Yin JK, Liang YM, He XL, et al: Fusion protein containing SH3 domain of c-Abl induces hepatocarcinoma cells to apoptosis. Hepatol Res 37: 454-463, 2007. (Pubitemid 46915790)
32. Ogura K, Shiga T, Yokochi M, Yuzawa S, Burke TR Jr and Inagaki F: Solution structure of the Grb2 SH2 domain complexed with a high-affinity inhibitor. J Biomol NMR 42: 197-207, 2008.
33. Dierck K, Machida K, Mayer BJ and Nollau P: Profiling the tyrosine phosphorylation state using SH2 domains. Methods Mol Biol 527: 131-155, 2009.
34. Jiang X, Huang F, Marusyk A and Sorkin A: Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol Biol Cell 14: 858-870, 2003. (Pubitemid 36337438)
35. Yamazaki T, Zaal K, Hailey D, Presley J, Lippincott-Schwartz J and Samelson LE: Role of Grb2 in EGF-stimulated EGFR internalization. J Cell Sci 115: 1791-1802, 2002. (Pubitemid 34567241)
36. Burke P, Schooler K and Wiley HS: Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell 12: 1897-1910, 2001. (Pubitemid 33049739)
37. Schulze WX, Deng L and Mann M: Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1: 2005.0008, 2005.
38. Seiden-Long I, Navab R, Shih W, et al: Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells. Carcinogenesis 29: 647-655, 2008. (Pubitemid 351404883)